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Toll-like receptorsosis (BV) have a higher risk of HIV transmission but the cause of risk is unknown.
Dendritic cells (DC) are implicated in transmission of HIV and we previously observed that DC mature when
exposed to mucosal ﬂuid from women with BV. We hypothesized that maturation of DC by BV mucosal ﬂuid
would enhance DC-mediated trans-infection of HIV.
Monocyte-derived DC (MDDC) were treated with mucosal ﬂuid, incubated with HIVBal, and HIV trans-
infection was evaluated. While LPS-treated MDDC increased HIVBal trans-infection, BV ﬂuid reduced trans-
infection. HIVBal DNA levels in MDDC were not affected by BV ﬂuid or LPS but productive infection of MDDC
was decreased by LPS and BV ﬂuid.
Mucosal ﬂuid fromwomen with BV does not increase MDDC-mediated trans-infection suggesting that BV
does not increase HIV susceptibility by increasing DC-mediated trans-infection. However, indirect effects of
DC maturation on HIV transmission cannot be ruled out.
© 2008 Elsevier Inc. All rights reserved.Introduction
Dendritic cells are believed to be an important target for HIV during
sexual transmission due to their presence at mucosal surfaces, their
function as antigen capturing cells and their role in initiating adaptive
immune responses by interacting with T cells (Piguet and Steinman,
2007). Experimental models of HIV sexual transmission show that DC
are one of the ﬁrst cells infected. Thus, 18 h after intravaginal
inoculation of macaques with SIV, SIV RNA can be detected in DC
isolated from the vaginal epithelium (Hu, Gardner, andMiller, 2000). In
an ex vivo human vaginal tissue culture system, HIV rapidly enters
Langerhans cells (Hladik et al., 2007) andDC in ex vivo cervical explants
take upHIV (Hu et al., 2004). DC can be directly infected byHIV but also
pass HIV to T cells (trans-infection) and maturation of DC induces an
increase in trans-infection (Granelli-Piperno et al., 1998; Izquierdo-
Useros et al., 2007; McDonald et al., 2003; Sanders et al., 2002).
Bacterial vaginosis (BV) is highly prevalent worldwide and is associated
with an increased risk for HIV acquisition (Cohen et al., 1995; Martin et al.,
1999;Myeretal., 2005;Sewankamboetal.,1997;Tahaetal.,1998).BVconsists/Microbiology, Rush University
, Room 636a, Chicago IL, USA.
ohn).
l rights reserved.of a shift in vaginal microbiota from predominantly lactobacilli in healthy
women to other bacteria that include both gram-positive and gram-negative
bacteria (Eschenbach et al., 1989; Fredricks, Fiedler, andMarrazzo, 2005). The
frequencyofBV inwomenof childbearingage inNorthAmericanpopulations
is between 5–30% and can be much higher in groups from some African
nations (Greenblatt et al., 1999; Schwebke, 2003; Sewankambo et al., 1997).
We previously observed that monocyte-derived DC (MDDC) are
activated andmaturedwhen exposed to themucosalﬂuid fromwomen
with BV (St John et al., 2007) and there have been several studies that
show that MDDC exposed to lipopolysaccharide (LPS) causes them to
mature and concomitantly increase their ability to mediate HIV trans-
infection (Granelli-Piperno et al., 1998; McDonald et al., 2003). We
therefore hypothesized that the association between BV and increased
sexual transmission of HIV could be due to increased trans-infection of
HIV to T cells caused by the activating/maturing effect that BV has on
DC. This study determinedwhethermucosalﬂuid fromwomenwith BV
increased in vitro HIV trans-infection of T cells mediated by MDDC.
Results
Mucosal ﬂuid from women with BV activate MDDC
To determine the effect of mucosal secretions on MDDC activation
and maturation, MDDCs were cultured with stimuli for 48 h and
Fig. 2. Effect of mucosal ﬂuids on MDDC-mediated trans-infection. MDDCs were
incubated with medium, LPS or CVL for 48 h, washed and followed by 2 h exposure to
HIV-1Bal. Unbound virus was removed by washing and PHA-stimulated PBMCs were
then added to MDDC inwells of a 96 well plate at a ratio of 1:3 (MDDC: PBMC). AZT was
added to some wells containing medium-treated MDDC and PHA-stimulated PBMC.
Supernatants were removed after 5 days of culture and analyzed for p24 by ELISA.
p values were determined by Wilcoxon matched-pairs signed-ranks test. Each data
point represents the average of triplicatewells from one independent experiment. Eight
different MDDC donors were used.
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Expression of CD83 and HLA-DR were signiﬁcantly increased due to
BV CVL when compared to medium (control) treated MDDC
(p=0.0286 and pb0.001 respectively, Mann Whiney test of eight
experiments) (Fig. 1). LPS-treated MDDC also had increased levels of
CD83 and HLA-DR compared to control, but these levels were not
signiﬁcantly different from BV CVL-treated MDDC. Normal CVL (CVL
fromwomenwith normal ﬂora— no BV) did not signiﬁcantly increase
CD83 or HLA-DR on MDDC compared to medium-treated MDDC.
AnnexinV/PI staining of MDDC was also analyzed following
treatments to determine if the MDDC were undergoing apoptosis or
cell death. Medium-treated MDDC were 17.3% positive for Annexin
plus PI dual staining. LPS, BV CVL or Normal CVL treatment did not
signiﬁcantly increase this level of staining (data not shown).
Mucosal ﬂuid from women with BV reduces MDDC-mediated
HIV-1Bal trans-infection of PBMC
Previous studies showed that LPS treatment of MDDCs increased
HIV trans-infection (Granelli-Piperno et al., 1998; McDonald et al.,
2003; Sanders et al., 2002). Since LPS and BV CVL both induced
activation and maturation of MDDC (Fig. 1), we hypothesized that BV
CVL would also increase trans-infection.
To test this, MDDC from8 different donorswere treatedwith either
Normal CVL or BV CVL were incubated with HIV for 2 h and then
cultured with PHA-stimulated PBMC for 5 days. Cultures with
medium-treated MDDC had median p24 levels of 55,703 pg/ml
whereas LPS-treatedMDDC had signiﬁcantly increased levels of p24 at
91,181 pg/ml (p=0.0068) (Fig. 2). Unexpectedly, p24 levels from
cultures with BV CVL-treated MDDC were signiﬁcantly lower than
medium-treated MDDC (21,835 pg/ml, p=0.001). Cultures with
Normal CVL-treated MDDC (44,344 pg/ml) had signiﬁcantly lower
p24 than LPS-treated MDDC (p=0.0068) but were not signiﬁcantly
different than medium-treated MDDC (Fig. 2). AZT treatment of
cultures reduced trans-infection to near background levels with
median value of 80 pg/ml (pb0.0001).
Experiments were also performed to determine if CVL samples had
a direct effect on HIV infection of CD4 T cells. Positively selected CD4 T
cells were incubatedwith CVL, infectedwith HIV and cultured. Neither
BV CVL or Normal CVL had a signiﬁcant effect on the amount of p24
measured in cultures after 5 days of culture (data not shown).
To determine if higher amounts of HIVBal added to BV CVL-treated
MDDC would lead to increased trans-infection, 2× or 4× more HIVBal
than were used in the Fig. 2 experiments were incubated with MDDC
before addition to PBMC. However, increasing the viral inoculumFig. 1. Effect of mucosal ﬂuid onMDDC expression of HLA-DR and CD83. MDDCs were incubat
were harvested and assessed by ﬂowcytometry for expression (Mean Fluorescence Intensity)
experiment of eight independent experiments is shown using MDDC from eight different dadded to BV CVL-treated MDDC did not increase trans-infection over
1× virus (data not shown).
BV mucosal ﬂuid decreased HIV infection of MDDC with HIV-1Bal
To investigate why BV CVL decreased MDDC-mediated trans-
infection while LPS increased trans-infection, the level of infection of
MDDC was analyzed. Previous reports showed that LPS decreased
MDDC infection (Cavrois et al., 2006; Granelli-Piperno et al., 1998;
McDyer et al., 1999). Both the level of productive infection and HIV
DNA formation were measured in MDDC after exposure to CVL.
Medium-treated MDDC from ﬁve different donors produced
2764 pg p24/ml (median) 5 days after infection (Fig. 3a). Exposure
to either BV CVL or LPS decreased p24 production to 395 and 609
respectively (pb0.001 and pb0.01 Repeated Measures ANOVA). In
contrast, p24 production from MDDC exposed to Normal CVL
(2005 pg/ml) was not signiﬁcantly different than medium control.
MDDC cultured with AZT was signiﬁcantly lower than all other
treatments at 107 pg/ml (pb0.001).
When HIV DNA formation in MDDC from the same ﬁve donors was
measured, medium-treated MDDC yielded 675 HIV DNA copies/50 nged for 48 h with either medium, LPS or CVL fromwomenwith BV or normal ﬂora. MDDC
of HLA-DR and CD83. Isotype control is shown in theMedium panel. One representative
onors.
Fig. 3. Effect of mucosal ﬂuids on HIV-1Bal infection of MDDC. MDDC were incubated for
48 h with either medium, LPS, CVL from women with BV or CVL from women with
normal ﬂora. (A) Cells were washed and infected with HIV-1Bal for 2 h. AZT (2 μM) was
added to some of the cultures containing medium-treated cells and maintained
throughout the duration of the experiment. Productive infection of MDDC measured by
p24 production in culture supernatants 5 days after infection. (B) Infection of MDDC
measured by HIV DNA formation in cells 24 h after infectionwith HIV-1Bal normalized to
GAPDH. Each point represents the average of triplicate wells from one independent
experiment and the line indicates the median value of each group. Five different MDDC
donors were used for these experiments. (A) p values were determined by the Friedman
test (A) and Repeated Measures Analysis of Variance (B).
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LPS and BV CVL did not signiﬁcantly affect HIV DNA levels (Fig. 3b).
There was, however, a signiﬁcant difference between the level of
medium treatment and AZT treatment of the MDDC (pb0.01).
Effect of BV mucosal ﬂuid on MDDC CCR5, DC-SIGN, PDL-1 and CD54
To further investigate the mechanism for the decreased trans-
infection following treatment of MDDC with BV mucosal ﬂuid,
expression of CCR5, DC-SIGN, PDL-1 and CD54 were assessed.
The level of CCR5 on MDDC was measured as this is a known co-
receptor for HIV-1 R5 viruses such as HIVBal. However, CCR5
expression was not affected by any of the treatments. CD209 (DC-
SIGN), a C-type lectin implicated in HIV trans-infection was
decreased on both LPS-treated and BV CVL-treated MDDC when
compared to medium-treated MDDC (MFI of 144 and 183 vs. 452
respectively) (Fig. 4).
PDL-1 is a costimulatory molecule present on DC that binds PD-1
on T cells and has been shown to inhibit T cell proliferation (Keir et. al.,
2007). PDL-1 was elevated on LPS-treated MDDC when compared to
medium-treated MDDC (MFI 524 vs. 153 respectively). PDL-1 on BV
CVL-treated MDDC (MFI 370) was also elevated when compared to
medium but was lower than LPS-treated MDDC (Fig. 4).
CD54 (ICAM-1) interacts with LFA-1 on T cells and has been
implicated as an important surface molecule in HIV trans-infection(Fortin et al., 1997; Sanders et al., 2002; Tardif and Tremblay, 2003). BV
CVL-treated MDDC expressed lower CD54 when compared to LPS
treatment of MDDC (MFI of 810 vs. 1560 respectively) (Fig. 4).
Discussion
Worldwide, women are the fastest growing group of people living
with and acquiring HIV-1/AIDS (UNAIDS, 2006). Women in sub-
Saharan Africa account for approximately 60% of all HIV-1 infected
individuals in that region (UNAIDS, 2006). Associations between BV
and the risk of HIV have been recognized since 1995 (Cohen et al.,
1995;Martin et al., 1999;Myer et al., 2005; Taha et al., 1999; Taha et al.,
1998), but a mechanism for enhanced risk has not been identiﬁed.
Dendritic cells have been identiﬁed as one of the ﬁrst cell types to
be infected with HIV during sexual transmission. DC are abundant in
the vaginal submucosa, and recent studies show that mucosal DC have
the ability to extend dendrites into the vaginal lumen to sample
luminal substances (Foti et. al., 2004). Our previous studies show that
MDDC are activated and matured following incubation with mucosal
ﬂuid fromwomenwith BV. We therefore hypothesized that similar to
LPS, exposure to BV CVL would increase the level of HIV trans-
infection. Surprisingly, we found a decrease of trans-infection.
Following activation of MDDC with BV CVL there was also decreased
productive infection of MDDC and there was no signiﬁcant change in
the level of infection as measured by HIV DNA content at 24 h. These
latter two results suggest that for BV CVL-treatedMDDC, at least a part
of the lower trans-infection may be due to lower “second phase” virus
transfer to T cells that occurs between 24 and 72 h postvirus pulse
described by Turville et al. (2004). Second phase inhibition would be
consistent with others who havemade the observation for the need of
infection of DCs prior to transfer to CD4+ lymphocytes (Kawamura
et al., 2000; Kawamura et al., 2003; Pope et al., 1995; Reece et al.,
1998).
MDDC can be induced to mature into different types of DC as
shown by Sanders et al. (2002) who demonstrated that incubation of
MDDC with varying stimuli induces maturation to either a Th1
promoting effector DC (DC1), Th2 promoting effector DC (DC2) or a DC
type with features of both (DC0) (Sanders et al., 2002). It was further
shown that these MDDC subtypes had differing abilities to be infected
by and transfer HIV. A decrease in both infection of MDDC and transfer
of HIV fromMDDC to T cells was shown by McDyer et al. (1999) when
MDDC were exposed to CD40LT which induced decreased reverse
transcriptase activity in a CC-chemokine dependent fashion. Our
results along with these previously published reports indicate that
different stimuli can have very different effects on HIV trans-infection
elicited by DC.
Women with BV have a large variety of bacteria in their vaginal
microbiota. These bacteria are both gram-negative (LPS) and gram-
positive (peptidoglycan and lipoteichoic acid) and therefore have
components for stimulation via TLR4 and TLR2 respectively. Previous
studies in our lab show that the TLR2 pathway is preferentially
stimulated by BV mucosal ﬂuids suggesting the involvement of gram-
positive products or other TLR2 ligands that could be inducing the
maturation of the MDDC (Mares et al., 2007). It has been reported that
lipoprotein (another TLR2 ligand) stimulation of MDDC induces high
levels of IL-12 (Thoma-Uszynski et al., 2000). We speculate that
stimulation via TLR2 ligands may induce activation/maturation of
MDDC to a DC2 phenotype and this phenotype is known to be less
prone to infection and viral transfer (Sanders et al., 2002). Thus, CD54
(ICAM-1) was only slightly increased on the BV CVL-stimulated MDDC
compared to medium alone. ICAM-1 is important for LFA-1 ICAM-1
interaction/cross talk between T cells and MDDC and was shown by
Sanders et al. (2002) to be a cell to cell interaction that is important for
HIV transmission between MDDC and T cells.
Our ﬁndings would suggest that the increased risk of HIV
transmission in women with BV is not due to stimulation of DC
Fig. 4. Effect of mucosal ﬂuids on levels of MDDC cell-surface markers. MDDCs were incubated with medium, LPS or CVL for 48 h. MDDC were harvested and assessed by ﬂow
cytometry for expression (Mean Fluorescence Intensity) of CCR5 (PE), CD209 (PE), PDL-1 (APC) and CD54 (PE). Isotype controls for the two different ﬂuorochromes are shown in
panels CCR5 (PE), PDL-1 (APC). One representative experiment of three independent experiments is shown using MDDCs from three different donors.
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activation by BV could induce local activation of T cells which could
increase HIV susceptibility. DC that become activated and matured by
mucosal secretions from women with BV, secrete elevated levels of
IL-12p70 and IL-23 (St John et al., 2007) and may express elevated
levels of other cytokines such as IL1α, IL-1β, IL-6, IL-7, IL-15, IL-18,
TNFα and TNFβ (de Saint-Vis et al., 1998) that could contribute to the
activation of T cells. IL-7 is of particular note because IL-7 from DC
induces the activation of T cells (Managlia et. al., 2005; Vasir et al.,
2005), and furthermore naïve T cells pre-incubated with IL-7 can be
productively infected with HIV (Managlia et. al., 2006). A recent
publication by Kawamura et al. (2008) shows that of three DC subsets
identiﬁed in human epithelial skin emigrants, Langerhans cells (LC)
accounted for greater than 95% of HIV dissemination. Therefore, LC
may be the critical cell initiating virus dissemination from the
epithelial layers to cells of the sub-epithelium and LC could react
differently to BVmucosal secretions than do DC, as they are a different
subset of DC with unique features and location. LC are located within
the epithelial layer of mucosal tissues at levels of between 2 and 4% of
the total cells present and express Langerin (CD207), CD1ahigh and
have the presence of Birbeck granules (Edwards and Morris, 1985;
Piguet and Steinman, 2007).In conclusion, we observed that vaginal mucosal ﬂuid fromwomen
with BV causes DC to reach a matured and activated state, but that
these cells have decreased ability to mediate trans-infection of T cells.
The data indicate the need for further research into the effects that BV
has on HIV target cells present in the lower genital tract that have
possible involvement in BV-associated HIV acquisition.
Material and methods
Patient samples
Cervical vaginal lavage (CVL) samples were obtainedwith informed
consent from a cohort of women attending a fertility clinic (UNICAMP,
Sao Paulo, Brazil). CVL were collected by irrigation of the cervix with
10ml of nonbacteriostatic sterile saline followed by aspiration from the
posterior fornix. CVL were centrifuged at 800×g for 20 min to remove
cell debris and stored at −80 °C. Gram stains of vaginal swabs were
evaluated using the Nugent criteria (Nugent et. al., 1991). Studies were
performed onlyon sampleswithNugent scores of 8–10 (positive for BV)
or scores of 0–3 (negative for BV, normal ﬂora). CVL were fromwomen
negative for yeast, Chlamydia, Neisseria gonorrhoeae and cervical
dysplasia (St John et al., 2007). The BV CVL used in this study was a
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while the Normal CVL was pooled from 17 women negative for BV.
DC generation and stimulation
Peripheral blood mononuclear cells (PBMC) were isolated from the
blood of healthy donors by centrifugation on Lymphocyte Separation
Medium (BioWhittaker, Walkerville, MD). The blood donors provided
informed consent and the study was approved by the Rush
institutional review board. Monocytes were isolated with CD14+
microbeads and the autoMACS cell separation system (Miltenyi Biotec,
Auburn, CA) yielding greater than 95% purity as determined by ﬂow
cytometry. Isolated monocytes were cultured in RPMI 1640 medium
supplemented with 10% heat inactivated Fetal Bovine Serum (FBS)
(BioWhittaker, Walkersville, MD), 2 mM L-Glutamine (BioWhittaker,
Walkersville, MD), 1000 U/ml GM-CSF (Leukine, Berlex, Richmond CA)
and 2900 U/ml IL-4 (R&D Systems, Minneapolis, MN) at 2×106
cells/ml for 6 days at 370 °C in 5% CO2 (McDonald et al., 2003; Sallusto
et al., 1995; Sallusto and Lanzavecchia, 1994; Thurner et al., 1999).
Cytokines were replenished on days 2 and 4. On day 6 the MDDCs
were harvested and cultured for a further 48 h (1×106 MDDC in 1 ml
total volume) with either medium alone, 1 μg/ml E. coli Lipopoly-
saccharide (LPS) (Sigma Aldrich, St. LouisMO) or CVL samples at 10% of
total culture volume (St John et al., 2007).
Virus
HIVBal obtained through the AIDS Research and Reference Reagent
Program (Division of AIDS, NIAID, NIH) was produced in PHA-
stimulated PBMCs using standard methods (ACTG, 2004). In brief,
PBMC were isolated from human blood and stimulated at 2×106
cells/ml with 4 μg/ml PHA with 20 U/ml IL-2 for 2 days. Virus was
added to stimulated PBMCs and supernatants of this culture were
harvested at days 5–11. The p24 and TCID50 of these cultures was then
assessed by p24 ELISA (HIV-1 p24 Antigen Capture Assay Kit, SAIC-
Frederick Inc., Frederick, MD).
Exposure of MDDC to HIV
MDDC stimulated for 48 h with LPS, CVL or medium were
harvested, washed and incubated at 37 °C with HIV-1Bal at 500
TCID50 for 2 h. MDDC were then washed twice with PBS and a third
time with medium and cultured at 105 cells/0.2 ml/well in 96 well
plates. Supernatants from each well were harvested on days 5 and 7
and tested for p24 levels (HIV-1 p24 Antigen Capture Assay Kit, SAIC-
Frederick Inc., Frederick, MD).
MDDC transfer of HIVBal to T cells
Transfer of HIV from MDDC to T cells was performed similar to
previous studies (Geijtenbeek et al., 2000; Pope et al., 1994). In brief,
while MDDC were being incubated with stimuli, PBMC from a healthy
donor were isolated and stimulated for 48 h with 4 μg/ml PHA and
20 U/ml IL-2. PHA-stimulated PBMC and virus-exposed MDDC were
added to triplicate wells at a ratio of 1:3 (33,000 MDDC: 100,000
PBMC). Some of the culture wells were incubated with 2 μM AZT for
1.5 h before mixing DC and PBMC and the level of AZT was maintained
throughout the experiment. Supernatants were harvested on days 5
and 7 for p24 ELISA.
Quantitative Real-Time PCR for measurements of HIV-1 DNA
Following the 48 h incubation with stimuli, 6×105 MDDC were
washed and incubated at 37 °C with HIV-1Bal at TCID50 2500 in tubes
in 200 μl culture medium. The tubes were shaken for the ﬁrst 2 h of
incubation followed by a further 24 h of culture. After infection, MDDCwere washed 3× with cold PBS and DNA isolated from cells (DNeasy
Blood & Tissue Kit, Qiagen, Valencia, CA). HIV DNA was quantiﬁed by
Real-Time PCR of the isolated DNA tissues using SYBR Green PCR core
Reagents (Applied Biosystems, Foster City, CA) and the Applied
Biosystems 7500 Real-Time PCR System. The ampliﬁcation reaction
was carried out in triplicate by using 1× SYBR Green, 2.5 mM MgCl2,
0.25 mM dNTPs, 0.04 μM primers, 0.01 U of UNG and 0.02 U of Taq
Polymerase in 50 μl of total volume. The following primers were used
as per Chun et al. (2003): 5′-GGTCTCTCTGGTTAGACCAGAT-3′ (5′
primer) and 5′CTGCTAGAGATTTTCCACACTG-3′ (3′ primer). DNA levels
were normalized using primers for human GAPDH.
Flow cytometric analysis of MDDC
After culture of MDDCwith stimuli for 48 h, cell-surface expression
of CD40, CD83, CD86, CD14, PDL-1, CCR5, CD54, CD209, and CCR7were
evaluated by ﬂow cytometry. The MDDC were identiﬁed as CD14−,
CD1a+ and HLA-DR+ (Relloso et al., 2002; Romani et al., 1996; Sallusto
and Lanzavecchia, 1994). Cell-surface markers were evaluated using
APC-conjugated monoclonal antibodies (mAb) to CD40, CD83, CD86,
CD14 (BD Pharmingen, San Jose, CA) PDL-1 (eBioscience, San Diego,
CA), PerCP-conjugated mAb to HLA-DR (BD Bioscience, San Jose, CA),
PE-conjugated mAbs to CCR5, CD54, CD209, CCR7 (BD Bioscience, San
Jose, CA) and FITC-conjugated mAb to CD1a (BD Bioscience, San Jose,
CA). All gates were set based on staining of isotype controls for each
ﬂuorochrome.
Statistical analysis
The Wilcoxon matched-pairs signed-ranks test, Repeated Mea-
sures Analysis of Variance, and the Friedman test were used to
determine statistically signiﬁcant differences between groups. The
analysis was performed using GraphPad Prism 4 software (San Diego,
CA).
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